The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...
Several generic drugmakers have submitted copycat Zytiga products for approval by the FDA, and one of these – India’s Sun Pharma – claimed approval for its Yonsa generic in May.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback